| Literature DB >> 29264487 |
Ioanna Kosteria1, George Th Tsangaris2, Alexandra Gkourogianni1, Athanasios Anagnostopoulos2, Aggeliki Papadopoulou2, Ioannis Papassotiriou3, Dimitrios Loutradis4, George P Chrousos1, Christina Kanaka-Gantenbein1.
Abstract
CONTEXT: Assisted reproduction technologies (ART), classic in vitro fertilization (IVF), and intracytoplasmic sperm injection (ICSI) are increasingly used. Several studies have demonstrated an unfavorable cardiometabolic profile of the ART offspring. Proteomics is a state-of-the-art technology used for the identification of early biomarkers of disease.Entities:
Keywords: ICSI; IVF; cardiometabolic; metabolism; proteomics
Year: 2017 PMID: 29264487 PMCID: PMC5686695 DOI: 10.1210/js.2016-1052
Source DB: PubMed Journal: J Endocr Soc ISSN: 2472-1972
Demographic and Auxological Data of ICSI and Normally Conceived (Control) Children
| Parameters | N (%) | |||
|---|---|---|---|---|
| ICSI | Control | |||
| Sex | Male (n = 38) | 19 | 19 | 0.999 |
| Female (n = 46) | 23 | 23 | ||
| No. of fetuses | Single (n = 49) | 13 | 36 | <0.0001 |
| Twin (n = 35) | 29 | 6 | ||
| Uneventful pregnancy | No (n = 31) | 20 | 11 | 0.09 |
| Yes (n = 49) | 22 | 27 | ||
| Breastfeeding | No (n = 23) | 11 | 12 | 0.86 |
| Yes (n = 60) | 30 | 30 | ||
| Type of delivery | Natural (n = 22) | 5 | 17 | 0.003 |
| Cesarean section (n = 62) | 37 | 25 | ||
| Birthweight for gestational age | SGA (n = 31) | 18 | 13 | 0.33 |
| AGA (n = 47) | 22 | 25 | ||
| Age (y) | 6.8 ± 2.05 | 6.8 ± 2.08 | 0.93 | |
| Mother’s age (y) | 35.6 ± 5.2 | 31.7 ± 5.3 | 0.0013 | |
| Father’s age (y) | 38.3 ± 5.4 | 35.9 ± 5.9 | 0.06 | |
| Gestational age (wk) | 35.6 ± 2.8 | 37.9 ± 1.8 | 0.0001 | |
| Birthweight SDS | −0.39 ± 0.95 | 0.42 ± 0.9 | 0.0001 | |
| Birth length SDS | −0.24 ± 1.03 | 0.24 ± 0.9 | 0.015 | |
| Height SDS | 0.17 ± 0.92 | −0.11 ± 0.99 | 0.17 | |
| Weight SDS | −0.09 ± 0.8 | −0.03 ± 0.96 | 0.7 | |
| BMI | −0.17 ± 0.95 | −0.02 ± 1.04 | 0.4 | |
| Waist/Height (W/H) | 0.48 ± 0.04 | 0.49 ± 0.05 | 0.5 | |
| Waist/Hip ratio (WHR) | 0.96 ± 0.06 | 0.94 ± 0.06 | 0.4 | |
| SBP SDS | 0.006 ± 0.9 | 0.83 ± 1.02 | 0.0004 | |
| DBP SDS | −0.37 ± 0.6 | −0.2 ± 0.65 | 0.2 | |
Abbreviations: AGA, appropriate for gestational age; DBP, diastolic blood pressure; SBP, systolic blood pressure.
Mann–Whitney test.
Normal distribution; two-sample t test.
Biochemical and Hormonal Data in ICSI and Naturally Conceived (Control) Groups
| Parameters | ICSI | Control | ||
|---|---|---|---|---|
| Glucose metabolism | Glucose (mg/dL) | 81 ± 7.7 | 83.7 ± 9.3 | 0.36 |
| Insulin (μIU/mL) | 5.5 ± 2.5 | 6.9 ± 6.7 | 0.9 | |
| Glucose/Insulin | 19 ± 15.1 | 18.9 ± 13.8 | 0.86 | |
| HOMA | 1.1 ± 0.5 | 1.5 ± 1.8 | 0.9 | |
| Lipid profile | Total cholesterol (mg/dL) | 167.7 ± 25.3 | 172.7 ± 24.5 | 0.35 |
| Triglycerides (mg/dL) | 45.4 ± 16.5 | 54.2 ± 22.6 | 0.07 | |
| HDL (mg/dL) | 63.9 ± 8.9 | 60.8 ± 12 | 0.17 | |
| LDL (mg/dL) | 94.6 ± 21.2 | 100.9 ± 22 | 0.18 | |
| ApoA1(mg/dL) | 153 ± 21.1 | 156.1 ± 19.8 | 0.5 | |
| ApoB (mg/dL) | 75.7 ± 14.7 | 74.2 ± 14.9 | 0.65 | |
| Lp(a) (mg/dL) | 11.8 ± 14.8 | 15.4 ± 20.3 | 0.16 | |
| Iron metabolism | Ht (%) | 39.5 ± 2.9 | 38.4 ± 2.2 | 0.07 |
| Hb (g/dL) | 13.1 ± 1.1 | 12.8 ± 0.8 | 0.22 | |
| Fe (μg/dL) | 71.9 ± 21.7 | 88.8 ± 38.9 | 0.1 | |
| Ferritin (μg/L) | 40.1 ± 24.6 | 38.4 ± 17.3 | 0.7 | |
| Hormones | Cortisol (μg/dL) | 12.5 ± 6.3 | 13.9 ± 7.4 | 0.42 |
| IGF1 (ng/mL) | 193.2 ± 115.3 | 190.5 ± 92.5 | 0.58 | |
| Τ3 (ng/dL) | 183.37 ± 27.1 | 158.58 ± 31.1 | <0.0001 | |
| Τ4 (μg/dL) | 8.6 ± 1.11 | 8.97 ± 1.16 | 0.06 | |
| TSH (μIU/mL) | 3.02 ± 1.3 | 3.24 ± 1.89 | 0.96 |
Abbreviations: HDL, high-density lipoprotein; HOMA, homeostasis model assessment; IGF, insulin-like growth factor; LDL, low-density lipoprotein; TSH, thyrotropin.
Normal distribution; two-sample Student t test.
List of Proteins That Were Identified by Matrix-Assisted Laser Desorption/Ionization Tandem Time of Flight Mass Spectrometer–Mass Spectrometry From the Spots That Were Selected as Differentially Expressed Between the Two Groups (ICSI and Natural Conception) After Two-Dimensional Electrophoresis (A, Individual Samples; B, Pooled Samples)
| α-1-Acid glycoprotein 1, OS = | A1AG1_HUMAN | 85 | 44 | 23,725 | 4,80 |
| α-1-Antitrypsin, OS = | A1AT_HUMAN | 168 | 51 | 46,878 | 5,30 |
| α-2-HS-glycoprotein, OS = | FETUA_HUMAN | 72 | 23 | 40,098 | 5,40 |
| α-2-macroglobulin, OS = | A2MG_HUMAN | 283 | 34 | 164,613 | 6,00 |
| Apolipoprotein A-I, OS = | APOA1_HUMAN | 274 | 68 | 30,759 | 5,50 |
| Apolipoprotein A-IV, OS = | APOA4_HUMAN | 73 | 14 | 45,371 | 5,20 |
| Apolipoprotein E, OS = | APOE_HUMAN | 172 | 61 | 36,246 | 5,50 |
| Complement C1s subcomponent, OS = | C1S_HUMAN | 80 | 18 | 78,174 | 4,70 |
| Complement C3, OS = | CO3_HUMAN | 256 | 28 | 188,569 | 6,00 |
| Complement factor B, OS = | CFAB_HUMAN | 80 | 18 | 86,847 | 6,70 |
| DAN domain family member 5, OS = | DAND5_HUMAN | 53 | 53 | 20,737 | 12,30 |
| Fibrinogen α chain, OS = | FIBA_HUMAN | 225 | 35 | 95,656 | 5,60 |
| Fibrinogen γ chain, OS = | FIBG_HUMAN | 216 | 62 | 52,106 | 5,30 |
| Gelsolin, OS = | GELS_HUMAN | 50 | 8 | 86,043 | 5,90 |
| Haptoglobin, OS = | HPT_HUMAN | 74 | 16 | 45,861 | 6,10 |
| Ig κ chain C region, OS = | IGKC_HUMAN | 73 | 75 | 11,773 | 5,50 |
| Keratin, type I cytoskeletal 10, OS = | K1C10_HUMAN | 68 | 22 | 59,020 | 5,00 |
| Keratin, type I cytoskeletal 9, OS = | K1C9_HUMAN | 147 | 41 | 62,255 | 5,00 |
| Keratin, type II cytoskeletal 1, OS = | K2C1_HUMAN | 77 | 24 | 66,170 | 8,82 |
| Plasminogen, OS = | PLMN_HUMAN | 321 | 43 | 93,247 | 7,30 |
| Prothrombin, OS = | THRB_HUMAN | 118 | 21 | 71,475 | 5,60 |
| Serotransferrin, OS = | TRFE_HUMAN | 366 | 57 | 79,280 | 7,00 |
| Serum albumin, OS = | ALBU_HUMAN | 334 | 59 | 71,317 | 5,90 |
| Vitamin D | VTDB_HUMAN | 276 | 56 | 54,526 | 5,30 |
| α-1-Antitrypsin, OS = | A1AT_HUMAN | 170 | 52 | 46,878 | 5,3 |
| Apolipoprotein A-I, OS = | APOA1_HUMAN | 75 | 36 | 30,759 | 5,5 |
| Apolipoprotein A-IV, OS = | APOA4_HUMAN | 101 | 30 | 45,371 | 5,2 |
| Fibrinogen γ chain, OS = | FIBG_HUMAN | 201 | 58 | 52,106 | 5,3 |
| Serum albumin, OS = | ALBU_HUMAN | 184 | 42 | 71,317.00 | 5,9 |
| Transthyretin, OS = | TTHY_HUMAN | 64 | 55 | 15,991 | 5,4 |
Abbreviations: GN, gene name; MS, mass spectrometry; MW, molecular weight; OS, organism species; PE, protein existence; pI, isoelectric point; SV, sequence version.
Maximum MASCOT score is presented.
List of Proteins That Were Differentially Expressed Between ICSI and Natural Conception Groups
| ICSI | |
|---|---|
| α-1-Acid glycoprotein | DAN domain family member 5 |
| α-1-Antitrypsin | Fibrinogen α chain |
| α-2-HS-glycoprotein | Plasminogen |
| α-2-Macroglobulin | |
| Apolipoprotein A-I | |
| Apolipoprotein A-IV | |
| Apolipoprotein E | |
| Complement C1s subcomponent | |
| Complement C3 | |
| Complement factor B | |
| Fibrinogen γ chain | |
| Gelsolin | |
| Haptoglobin | |
| Ig κ chain C region | |
| Keratin, type I cytoskeletal 10 | |
| Keratin, type I cytoskeletal 9 | |
| Keratin, type II cytoskeletal 1 | |
| Prothrombin | |
| Serotransferrin | |
| Serum albumin | |
| Transthyretin | |
| Vitamin D–binding protein | |
Figure 1.Representation of functional classification of identified, differentially expressed proteins (% total number of identified proteins). Proteins were classified according to their major functions according to the uniprot database.
Figure 2.Interaction networks and enriched functional annotations of proteins differentially expressed in examined samples. Thicker network lines demonstrate strong protein relations, as well as neighboring positions. Α2Μ, α2-macroglobulin; AHSG, α2-HS glycoprotein; APOA1, apolipoprotein A-I; APOA4, apolipoprotein A-IV; APOE, apolipoprotein E; C1S, complement component 1; F2, prothrombin; FGG, fibrinogen γ chain; GC, vitamin D–binding protein; GSN, gelsolin; HP, haptoglobin; KRT1, keratin 1 (keratin type ΙΙ cytoskeletal 1); KRT9, keratin 9; KRT10, keratin 10; ORM1, α1 glycoprotein; SERPINA1, α1-antithrypsin; TF, transferrin; ΤTR, transthyretin.